Xin Hu

6.0k total citations · 3 hit papers
78 papers, 3.9k citations indexed

About

Xin Hu is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Xin Hu has authored 78 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Molecular Biology, 36 papers in Cancer Research and 16 papers in Oncology. Recurrent topics in Xin Hu's work include Cancer-related molecular mechanisms research (15 papers), RNA modifications and cancer (11 papers) and Cancer Genomics and Diagnostics (9 papers). Xin Hu is often cited by papers focused on Cancer-related molecular mechanisms research (15 papers), RNA modifications and cancer (11 papers) and Cancer Genomics and Diagnostics (9 papers). Xin Hu collaborates with scholars based in China, United States and Switzerland. Xin Hu's co-authors include Da‐Qiang Li, T Maciag, Robert Friesel, Yi‐Rong Liu, Ding Ma, Yi Xiao, Yi‐Zhou Jiang, William H. Shelver, Zhi-Ming Shao and Ke‐Da Yu and has published in prestigious journals such as Cell, Nucleic Acids Research and Journal of Biological Chemistry.

In The Last Decade

Xin Hu

74 papers receiving 3.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Metabolic-Pathway-Based Subtyping of Triple-Negative Breast Cancer Reveals Potential Therapeutic Targets

2020 296 citations Yue Gong, Tian‐Jian Yu et al. profile →
The microbial metabolite trimethylamine N-oxide promotes antitumor immunity in triple-negative breast cancer

2022 275 citations Hai Wang, Yi Xiao et al. profile →
Comprehensive metabolomics expands precision medicine for triple-negative breast cancer

2022 202 citations Yi Xiao, Jia-Han Ding et al. Cell Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Xin Hu China	34	2.5k	1.5k	1.1k	624	428	78	3.9k
Chih‐Yang Wang Taiwan	32	2.3k 0.9×	1.1k 0.7×	1.1k 1.0×	672 1.1×	408 1.0×	108	3.6k
Gennadi V. Glinsky United States	32	2.8k 1.1×	825 0.6×	1.0k 1.0×	467 0.7×	457 1.1×	75	4.1k
Uma Shankavaram United States	33	2.1k 0.8×	950 0.6×	985 0.9×	508 0.8×	295 0.7×	96	3.6k
Shan Zha United States	37	3.3k 1.3×	947 0.6×	1.6k 1.5×	618 1.0×	667 1.6×	78	4.6k
Zhuchu Chen China	34	2.7k 1.1×	779 0.5×	836 0.8×	339 0.5×	336 0.8×	166	3.7k
Zhi-Ming Shao China	32	2.1k 0.8×	1.3k 0.9×	1.2k 1.1×	467 0.7×	447 1.0×	60	3.6k
Donatella Del Bufalo Italy	42	3.0k 1.2×	1.0k 0.7×	1.4k 1.3×	350 0.6×	650 1.5×	133	4.7k
Jinfang Zhang China	33	2.3k 0.9×	736 0.5×	1.4k 1.3×	729 1.2×	628 1.5×	73	3.8k
Yujuan Zhou China	34	3.0k 1.2×	2.0k 1.3×	1.1k 1.0×	560 0.9×	829 1.9×	72	4.6k

Countries citing papers authored by Xin Hu

Since Specialization

Citations

This map shows the geographic impact of Xin Hu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xin Hu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xin Hu more than expected).

Fields of papers citing papers by Xin Hu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xin Hu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xin Hu. The network helps show where Xin Hu may publish in the future.

Co-authorship network of co-authors of Xin Hu

This figure shows the co-authorship network connecting the top 25 collaborators of Xin Hu. A scholar is included among the top collaborators of Xin Hu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xin Hu. Xin Hu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wu, Min, et al.. (2025). The E3 ubiquitin ligase SIAH1 targets a bacterial pore-forming toxin to facilitate xenophagy. Cell Reports. 44(9). 116257–116257.

Hu, Xin, et al.. (2025). LncRNA HOXA10-AS as a novel biomarker and therapeutic target in human cancers. Frontiers in Molecular Biosciences. 11. 1520498–1520498.

Li, Xiaoguang, Yue Gong, Shiqi Mao, et al.. (2025). Metformin sensitizes triple-negative breast cancer to histone deacetylase inhibitors by targeting FGFR4. Journal of Biomedical Science. 32(1). 36–36. 4 indexed citations

Zhang, Xinhui, Bilal Ahmad, Yaqi Lan, et al.. (2024). Genome-Wide Characterization of Shi-Related Sequence Gene Family and Its Roles in Response to Zn2+ Stress in Cucumber. Horticulturae. 10(11). 1154–1154.

Li, Hongquan, Yifei He, Yizhe Liu, et al.. (2022). CRISPR/Cas9 Screens Reveal that Hexokinase 2 Enhances Cancer Stemness and Tumorigenicity by Activating the ACSL4‐Fatty Acid β‐Oxidation Pathway. Advanced Science. 9(21). e2105126–e2105126. 52 indexed citations

Ma, Ding, Siyu Chen, Yu‐Chen Pei, et al.. (2020). Molecular Features and Functional Implications of Germline Variants in Triple-Negative Breast Cancer. JNCI Journal of the National Cancer Institute. 113(7). 884–892. 28 indexed citations

Liu, Yin, Yi Xiao, Xin Hu, et al.. (2020). Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial. Cell Research. 31(2). 178–186. 194 indexed citations

Cao, Dalong, Zihao Qi, Yangyang Pang, et al.. (2019). Retinoic Acid–Related Orphan Receptor C Regulates Proliferation, Glycolysis, and Chemoresistance via the PD-L1/ITGB6/STAT3 Signaling Axis in Bladder Cancer. Cancer Research. 79(10). 2604–2618. 102 indexed citations

Xiao, Yi, Ding Ma, Shen Zhao, et al.. (2019). Multi-Omics Profiling Reveals Distinct Microenvironment Characterization and Suggests Immune Escape Mechanisms of Triple-Negative Breast Cancer. Clinical Cancer Research. 25(16). 5002–5014. 265 indexed citations

10.

Yang, Haiyuan, Ding Ma, Yihua Sun, et al.. (2019). Integration of whole‐genome sequencing and functional screening identifies a prognostic signature for lung metastasis in triple‐negative breast cancer. International Journal of Cancer. 145(10). 2850–2860. 15 indexed citations

11.

Jin, Xi, Xiao‐En Xu, Yi-Zhou Jiang, et al.. (2019). The endogenous retrovirus-derived long noncoding RNA TROJAN promotes triple-negative breast cancer progression via ZMYND8 degradation. Science Advances. 5(3). eaat9820–eaat9820. 96 indexed citations

12.

Zhu, Yifei, Mingxu Xie, Lai K. Leung, et al.. (2019). Knockdown of TM9SF4 boosts ER stress to trigger cell death of chemoresistant breast cancer cells. Oncogene. 38(29). 5778–5791. 25 indexed citations

13.

Zheng, Yi-Zi, Hongjie Shen, Ding Ma, et al.. (2018). PHF5A Epigenetically Inhibits Apoptosis to Promote Breast Cancer Progression. Cancer Research. 78(12). 3190–3206. 65 indexed citations

14.

Yu, Tian‐Jian, Yingying Liu, Xin Hu, & Gen‐Hong Di. (2018). No survival improvement of contralateral prophylactic mastectomy among women with invasive lobular carcinoma. Journal of Surgical Oncology. 118(6). 928–935. 7 indexed citations

15.

Liu, Yi‐Rong, Yi-Zhou Jiang, Xiao‐En Xu, et al.. (2016). Comprehensive Transcriptome Profiling Reveals Multigene Signatures in Triple-Negative Breast Cancer. Clinical Cancer Research. 22(7). 1653–1662. 71 indexed citations

16.

Zhu, Tongyu, Haojie Zhang, Tao Jing, et al.. (2016). Twist2 promotes kidney cancer cell proliferation and invasion by regulating ITGA6 and CD44 expression in the ECM-receptor interaction pathway. OncoTargets and Therapy. 9. 1801–1801. 55 indexed citations

17.

Tan, Wilson Wei Sheng, et al.. (2015). Berberine interfered with breast cancer cells metabolism, balancing energy homeostasis. Scopus. 15(1). 1 indexed citations

18.

Gao, Shuiping, Hefen Sun, Honglin Jiang, et al.. (2015). Loss of TIM50 suppresses proliferation and induces apoptosis in breast cancer. Tumor Biology. 37(1). 1279–1287. 20 indexed citations

19.

He, Min, Xin Hu, Li Chen, et al.. (2014). A recessive variant of XRCC4 predisposes to non-BRCA1/2 breast cancer in chinese women and impairs the DNA damage response via dysregulated nuclear localization. Oncotarget. 5(23). 12218–12232. 5 indexed citations

20.

Zhou, Juan, Xingbo Song, Dongdong Li, et al.. (2011). Association Between Two Genetic Variants in miRNA and Primary Liver Cancer Risk in the Chinese Population. DNA and Cell Biology. 31(4). 524–530. 62 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact